Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir(®) therapy: A case report

Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir(®) as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression‐free survival are good.

Detalles Bibliográficos
Autores principales: Pumpure, Elizabete, Dručka, Eva, Kigitoviča, Dana, Meškauskas, Raimundas, Isajevs, Sergejs, Nemiro, Ineta, Rasa, Agnija, Olmane, Evija, Zablocka, Tatjana, Alberts, Pēteris, Doniņa, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455402/
https://www.ncbi.nlm.nih.gov/pubmed/32884791
http://dx.doi.org/10.1002/ccr3.2928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455402/
https://www.ncbi.nlm.nih.gov/pubmed/32884791
http://dx.doi.org/10.1002/ccr3.2928

Ejemplares similares